Gilead's Breast Cancer Drug Gets U.S. FDA Approval for Third Indication
Per Reuters, Gilead Sciences shared FDA has approved the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.
The drug was approved for an advanced form of breast cancer with a subtype known as HR-positive/HER2-negative in patients, who had stopped responding to a hormone-based therapy and at least two earlier systemic therapies.
Sales of the drug, already approved for a type of breast and bladder cancer in the United States, nearly doubled to $680 million in 2022 from $380 million a year earlier. Analysts on average expect Trodelvy sales to reach $955.3 million in 2023, according to Refinitiv.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
